Altimmune annual ebitda
2010
2011
2012
2019
2020
2021
Altimmune EBITDA Growth & History (ALT)
Altimmune's calculated EBITDA was −$96.4M for fiscal 2021.
View full Altimmune company overviewAltimmune annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2021 | 2021-12-31 | −$96.4M | −$42.0M | — |
| 2020 | 2020-12-31 | −$54.4M | −$33.3M | — |
| 2019 | 2019-12-31 | −$21.1M | −$15.1M | — |
| 2012 | 2012-12-31 | −$6.0M | $5.3M | — |
| 2011 | 2011-12-31 | −$11.3M | $11.3M | — |
| 2010 | 2010-12-31 | −$22.5M | — | — |
Altimmune quarterly ebitda
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q3 2022 | 2022-09-30 | −$24.9M | $8.0M | — |
| Q2 2022 | 2022-06-30 | −$20.3M | $4.4M | — |
| Q1 2022 | 2022-03-31 | −$19.4M | −$4.6M | — |
| Q4 2021 | 2021-12-31 | −$23.9M | −$13.3M | — |
| Q3 2021 | 2021-09-30 | −$32.9M | −$14.7M | — |
| Q2 2021 | 2021-06-30 | −$24.8M | −$6.4M | — |
| Q1 2021 | 2021-03-31 | −$14.8M | −$7.6M | — |
| Q4 2020 | 2020-12-31 | −$10.5M | −$9.1M | — |
| Q3 2020 | 2020-09-30 | −$18.3M | −$17.2M | — |
| Q2 2020 | 2020-06-30 | −$18.3M | −$17.0M | — |
| Q1 2020 | 2020-03-31 | −$7.2M | −$5.5M | — |
| Q2 2013 | 2013-06-30 | −$1.4M | −$58,119 | — |
| Q1 2013 | 2013-03-31 | −$1.0M | $466,654 | — |
| Q4 2012 | 2012-12-31 | −$1.4M | −$387,706 | — |
| Q3 2012 | 2012-09-30 | −$1.7M | $1.2M | — |
| Q2 2012 | 2012-06-30 | −$1.4M | $1.6M | — |
| Q1 2012 | 2012-03-31 | −$1.5M | $2.9M | — |
| Q4 2011 | 2011-12-31 | −$970,302 | $2.1M | — |
| Q3 2011 | 2011-09-30 | −$2.9M | $2.4M | — |
| Q2 2011 | 2011-06-30 | −$3.0M | — | — |
| Q1 2011 | 2011-03-31 | −$4.4M | — | — |
| Q3 2010 | 2010-09-30 | −$3.1M | — | — |
| Q2 2010 | 2010-06-30 | −$5.3M | — | — |
Altimmune ebitda trends
Over the last five reported fiscal years, Altimmune's ebitda decreased from −$22.5M to −$96.4M, a change of −$73.8M. The latest reported quarter, Q3 2022, shows −$24.9M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Altimmune filings at SEC.gov ↗